ADMA

#1975
ADMA Biologics Inc - Common Stock
9.3 4 USD
-0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
9.34
9.34
Jahresspanne
7.21
20.46
Tagesänderung
-1.48%
Monatliche Änderung
+8.73%
6 month change
-40.51%
Jahresänderung
-45.35%
Vorheriger Schlusskurs
9.4 8
Open
9.3 4
Tief
9.3 4
Hoch
9.3 4
Volumen
178
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
ADMA BIOLOGICS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
ADMA BIOLOGICS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
ADMA BIOLOGICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ADMA BIOLOGICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ADMA BIOLOGICS, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
ADMA BIOLOGICS, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
ADMA BIOLOGICS, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
ADMA BIOLOGICS, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
ADMA BIOLOGICS, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
ADMA BIOLOGICS, INC. current report, Q1 FY2026
8-K

ADMA BIOLOGICS, INC. current report, Q2 FY2025

Full document

ADMA Biologics, Inc. 8-K Summary

Business Context and Reporting Period

This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held on June 4, 2025. The filing details the outcomes of four proposals submitted to security holders, including director elections, auditor ratification, and executive compensation advisory votes.

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and voting results.

Material Changes and Voting Results

At the Annual Meeting, 205,020,539 shares were represented, constituting a quorum out of 238,563,612 shares outstanding as of the April 8, 2025 record date. The following matters were approved:

  • Director Election: Two Class III directors were elected to serve until the 2028 Annual Meeting.
    • Jerrold B. Grossman: 165,120,823 votes For; 16,472,081 votes Withheld.
    • Lawrence P. Guiheen: 133,835,725 votes For; 47,757,179 votes Withheld.
  • Auditor Ratification: KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025 (204,623,833 For; 269,649 Against).
  • Say-on-Pay: The advisory vote on executive compensation was approved (161,456,980 For; 19,869,072 Against).
  • Say-on-Frequency: Stockholders voted to hold future advisory votes on executive compensation annually (173,069,853 votes for 1 Year).

Guidance, Outlook, and Risks

The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It is a procedural report of the Annual Meeting outcomes.

Investor Verification Checklist

  • Verify the tenure of the newly elected Class III directors (Jerrold B. Grossman and Lawrence P. Guiheen) through the 2028 Annual Meeting.
  • Confirm the appointment of KPMG LLP as the independent auditor for the fiscal year ending December 31, 2025.
  • Note the significant number of broker non-votes (23,427,635) recorded for the director election and Say-on-Pay proposals.
  • Review the substantial "Withheld" votes for Lawrence P. Guiheen (47,757,179) compared to Jerrold B. Grossman (16,472,081).

Nachrichten